Wesley R Armstrong1, Andrei Gafita1, Shaojun Zhu1, Pan Thin1, Kathleen Nguyen1, Rejah Alano1, Stephanie Lira1, Kiara Booker1, Linda Gardner1, Tristan Grogan2, David Elashoff2, Martin Allen-Auerbach1,3,4, Magnus Dahlbom1,5, Johannes Czernin1,3,4,5, Jeremie Calais6,3,4,5. 1. Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California. 2. Department of Medicine Statistics Core, David Geffen School of Medicine, UCLA, Los Angeles, California. 3. Institute of Urologic Oncology, UCLA, Los Angeles, California. 4. Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California; and. 5. Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California. 6. Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California; jcalais@mednet.ucla.edu.
Abstract
The prostate-specific membrane antigen (PSMA) has been targeted for PET imaging and radioligand therapy (RLT) in patients with prostate cancer. Xerostomia is a common side effect of RLT because of the high salivary gland uptake of PSMA radioligands. Here, we aimed to determine the impact of monosodium glutamate (MSG) administration on PSMA-radioligand biodistribution within healthy organs and tumor lesions by using 68Ga-PSMA-11 PET imaging. Methods: Sixteen men with prostate cancer were randomized (1:1) into oral ingestion and oral topical application ("swishing") arms. Each subject underwent 2 68Ga-PSMA-11 PET/CT scans within 14 d under baseline and MSG conditions. The salivary glands and whole-body tumor lesions were segmented using qPSMA software. We quantified tracer uptake via SUVmean and SUVmax and compared parameters within each patient. Results: For the oral ingestion arm, salivary gland SUVmean and SUVmax decreased on average from the control scan to the MSG scan by 45% ± 15% (P = 0.004) and 53% ± 11% (P < 0.001), respectively. Tumor lesion SUVmean and SUVmax also decreased by 38% (interquartile range, -67% to -33%) and -52% (interquartile range, -70% to -49%), respectively (P = 0.018). Swishing had no significant effect on 68Ga-PSMA-11 accumulation in normal organs or tumor lesions. Conclusion: Oral ingestion but not topical application of MSG reduced 68Ga-PSMA-11 uptake in salivary glands. Tumor uptake also declined; therefore, the clinical application of MSG is unlikely to be useful in the framework of RLT.
The prostate-specific membrane antigen (PSMA) has been targeted for PET imaging and radioligand therapy (RLT) in patients with prostate cancer. Xerostomia is a common side effect of RLT because of the high salivary gland uptake of PSMA radioligands. Here, we aimed to determine the impact of monosodium glutamate (MSG) administration on PSMA-radioligand biodistribution within healthy organs and tumor lesions by using 68Ga-PSMA-11 PET imaging. Methods: Sixteen men with prostate cancer were randomized (1:1) into oral ingestion and oral topical application ("swishing") arms. Each subject underwent 2 68Ga-PSMA-11 PET/CT scans within 14 d under baseline and MSG conditions. The salivary glands and whole-body tumor lesions were segmented using qPSMA software. We quantified tracer uptake via SUVmean and SUVmax and compared parameters within each patient. Results: For the oral ingestion arm, salivary gland SUVmean and SUVmax decreased on average from the control scan to the MSG scan by 45% ± 15% (P = 0.004) and 53% ± 11% (P < 0.001), respectively. Tumor lesion SUVmean and SUVmax also decreased by 38% (interquartile range, -67% to -33%) and -52% (interquartile range, -70% to -49%), respectively (P = 0.018). Swishing had no significant effect on 68Ga-PSMA-11 accumulation in normal organs or tumor lesions. Conclusion: Oral ingestion but not topical application of MSG reduced 68Ga-PSMA-11 uptake in salivary glands. Tumor uptake also declined; therefore, the clinical application of MSG is unlikely to be useful in the framework of RLT.
Authors: B Emami; J Lyman; A Brown; L Coia; M Goitein; J E Munzenrider; B Shank; L J Solin; M Wesson Journal: Int J Radiat Oncol Biol Phys Date: 1991-05-15 Impact factor: 7.038
Authors: Michal Navrátil; Jakub Ptáček; Pavel Šácha; Jana Starková; Jacek Lubkowski; Cyril Bařinka; Jan Konvalinka Journal: FEBS J Date: 2014-06-17 Impact factor: 5.542
Authors: Sara Harsini; Heather Saprunoff; Tina Alden; Behnoud Mohammadi; Don Wilson; François Bénard Journal: J Nucl Med Date: 2020-05-08 Impact factor: 10.057
Authors: Hendrik Rathke; Clemens Kratochwil; Ralph Hohenberger; Frederik Lars Giesel; Frank Bruchertseifer; Paul Flechsig; Alfred Morgenstern; Matti Hein; Peter Plinkert; Uwe Haberkorn; Olcay Cem Bulut Journal: Eur J Nucl Med Mol Imaging Date: 2018-08-27 Impact factor: 9.236
Authors: Haofan Wang; Youngjoo Byun; Cyril Barinka; Mrudula Pullambhatla; Hyo-Eun C Bhang; James J Fox; Jacek Lubkowski; Ronnie C Mease; Martin G Pomper Journal: Bioorg Med Chem Lett Date: 2009-10-24 Impact factor: 2.823
Authors: Jyoti Roy; Blake M Warner; Falguni Basuli; Xiang Zhang; Changyu Zheng; Corrine Goldsmith; Tim Phelps; Karen Wong; Anita T Ton; Rick Pieschl; Margaret E White; Rolf Swenson; John A Chiorini; Peter L Choyke; Frank I Lin Journal: EJNMMI Res Date: 2021-07-21 Impact factor: 3.138
Authors: Mike M Sathekge; Frank Bruchertseifer; Mariza Vorster; Alfred Morgenstern; Ismaheel O Lawal Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-26 Impact factor: 9.236